Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Next-generation RNA QC System

By Drug Discovery Trends Editor | February 23, 2010

Lab901 has shipped the first of its next-generation ScreenTape systems for automated RNA QC to Oxford Gene Technology (OGT) in Oxford, UK. ScreenTape R6K is a next-generation platform for RNA QC that automatically delivers the ScreenTape Degradation Value (SDV), an objective quality metric for total RNA samples. Lab901’s ScreenTape platform eliminates steps such as gel reagent preparation, chip priming and chip-vortexing, and avoids all problems associated with cross priming and sample carry-over since individual micro-gels are used for each sample analysis.

“As OGT’s microarray R&D and service business grows, we are continually seeking opportunities to increase throughput whilst maintaining the highest standards of data quality,” commented John Anson, R&D Director at OGT. “Having evaluated Lab901’s ScreenTape platform, we are keen to integrate it into our high throughput microarray facility.” Commenting on the placement, Richard Rowling, Lab901’s Sales and Marketing Director said: “Being the pioneer of microarray-based technologies, we are particularly delighted that OGT has decided to add ScreenTape R6K to their RNA QC workflow.”

Unlike the leading chip-based systems, Lab901’s ScreenTape device can be used more than once. A single sample can be run cost-effectively each time, reserving the rest of the available channels for future experiments. There is no longer any need to batch samples together or throw away unused portions of the consumable, which improves the RNA QC workflow and saves money.

Lab901


Filed Under: Drug Discovery

 

Related Articles Read More >

Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study
Novartis in the Pharma 50
Novartis to cut up to 8,000 positions
Gilead Sciences in the Drug Discovery & Development Pharma 50
Gilead resubmits application to FDA for twice-yearly HIV drug lenacapavir
George Floyd mural
How the pandemic and George Floyd made clinical trial diversity a priority

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50